Search

Your search keyword '"Berntorp, E"' showing total 1,068 results
Start Over Author "Berntorp, E"
1,068 results on '"Berntorp, E"'

9. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Author

Berntorp E, Spotts G, Patrone L, and Ewenstein BM

Subjects
Medicine (General), R5-920
Abstract

Erik Berntorp,1 Gerald Spotts,2 Lisa Patrone,2 Bruce M Ewenstein2 1Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden; 2Baxter Healthcare Corporation, Westlake Village, CA, USA Abstract: Detailed analysis of data from studies of recombinant antihemophilic factor produced using a plasma/albumin-free method (rAHF-PFM) in previously treated patients showed a substantial level of interpatient variation in pharmacokinetics (PKs), factor VIII dosing, and annualized bleed rate (ABR), suggesting that individual patient characteristics contributed to outcome. For example, plasma half-life (t1/2), recovery, and clearance appeared to differ between patients aged

Published
2014

20. Hypertension, haematuria and renal functioning in haemophilia – a cross-sectional study in Europe

Author

HOLME, P. A., COMBESCURE, C., TAIT, R. C., BERNTORP, E., RAUCHENSTEINER, S., DE MOERLOOSE, P., PABINGER-FASCHING, Ingrid, HERMANS, Cedric, DʼOIRON, Roseline, NEGRIER, Claude, KLAMROTH, Robert, MARQUARDT, Natascha, STARITZ, Peter, MARTINOWITZ, Uri, KENET, Gili, LUBETSKY, Aharon, CANNAVÒ, Nino, TAGLIAFERRI, Annarita, SCHUTGENS, Roger, WINDYGA, Jerzy, ZUPAN, Irena, NÚÑEZ, Ramiro, and DOLAN, Gerry

Published
2016
Full Text
View/download PDF

38. Bleeding symptoms in patients diagnosed as type 3 von willebrand disease: results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study

Author

Tosetto, A., Badiee, Z., Baghaipour, M., Baronciani, L., Battle, J., Berntorp, E., Bodó, I., Budde, U., Castaman, G., Eikenboom, J.C.J., Eshghi, P., Ettorre, C., Goodeve, A., Goudemand, J., Charles Richard Morris, H., Hoorfar, H., Karimi, M., Keikhaei, B., Lassila, R., Leebeek, F.W.G., Lopez Fernandez, M.F., Mannucci, P.M., Mazzucconi, M.G., Morfini, M., Oldenburg, J., Peake, I., Parra Lòpez, R., Peyvandi, F., Schneppenheim, R., Tiede, A., Toogeh, G., Trossaert, M., Zekavat, O., Zetterberg, E.M.K., and Federici, A.B.

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, hemic and lymphatic diseases
Abstract

Background\ud Type 3 von Willebrand’s disease (VWD) patients present markedly reduced levels of von Willebrand factor and factor VIII. Because of its rarity, the bleeding phenotype of type 3 VWD is poorly described, as compared to type 1 VWD.\ud \ud Aims\ud To evaluate the frequency and the severity of bleeding symptoms across age and sex groups in type 3 patients and to compare these with those observed in type 1 VWD patients; to investigate any possible clustering of bleeding symptoms within type 3 patients.\ud \ud Methods\ud We compared the bleeding phenotype and computed the bleeding score (BS) using the MCMDM‐1VWD bleeding questionnaire in patients enrolled in the 3WINTERS‐IPS and MCMDM‐1VWD studies.\ud \ud Results\ud In 223 unrelated type 3 VWD patients, both the BS and the number of clinically relevant bleeding symptoms were increased in type 3 as compared to type 1 VWD patients (15. vs. 6.0 and 5 vs. 3). Intracranial bleeding, oral cavity, hemarthroses, and deep hematomas were at least five‐fold over‐represented in type 3 VWD. A more severe bleeding phenotype was evident in patients having VWF:Ag levels

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results